Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer
Chunlan Pu, Yu Tong, Yuanyuan Liu, Suke Lan, Shirui Wang, Guoyi Yan, Hongjia Zhang, Dan Luo, Xinyu Ma, Su Yu, Qing Huang, Rui Deng, Rui Li
Topics & Concepts
OlaparibPARP inhibitorTriple-negative breast cancerPARP1Homologous recombinationCancer researchChemistryUbiquitin ligaseIn vivoCancerBreast cancerPoly ADP ribose polymeraseBiologyUbiquitinDNAGeneticsBiochemistryPolymeraseGeneProtein Degradation and InhibitorsPARP inhibition in cancer therapyIntegrated Circuits and Semiconductor Failure Analysis